Skip to main content Skip to main navigation menu Skip to site footer

Fibroblast growth factor 2 expression on lymph node metastasis in early-stage breast cancer

  • Diani Kartini ,
  • Sonar Soni Panigoro ,
  • Islam Akbar Alam ,
  • Alban Willian Dien ,
  • Dewi Sumaryani Soemarko ,
  • Tantri Hellyanti ,
  • Jessica Dewati Wardhana ,
  • Kevin Varian Marcevianto ,


Abstract

Introduction: Axillary lymph node involvement is an important aspect of breast cancer diagnosis in determining treatment and predicting distant metastasis. Lymph node metastasis is associated with higher recurrence and survival rates. Lymph node status is a significant prognostic factor and is widely used. Several factors affect lymph node metastasis, including tumor size, grade, and invasive ductal histological type. FGF2, a lymphangiogenesis factor, influences the occurrence of lymph node metastasis. The present study aimed to determine the association between FGF2 expression and axillary lymph node metastasis in early-stage breast cancer and evaluate the association between FGF2 expression and clinicopathologic factors.

Methods: A cross-sectional design was used to evaluate the expression of FGF2 in 47 early-stage breast cancer patients who underwent either a mastectomy or breast-conserving surgery procedure at Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, from January 2014 to December 2018. FGF2 expression was examined by immunohistochemistry.

Results: FGF2 expression was significantly correlated with axillary lymph node metastasis incidence [p = 0.044, odds ratio 4.22 (95% CI 0.983-18.1)]. Higher FGF2 expression was significantly correlated with the grade, subtype, estrogen receptor (ER) status, and progesterone receptor (PR) status of the tumor (p = 0.017, p = 0.031, p = 0.002, p = 0.013, respectively).

Conclusions: Increased FGF2 expression and tumor size significantly correlated with axillary lymph node metastasis. The tumor's grade, intrinsic subtype, ER and PR status were significantly correlated with increased FGF2 expression. Our study indicated that FGF2 expression might aid in determining the presence of axillary lymph node metastasis.

Keywords: axillary lymph node metastases FGF2 early-stage breast cancer

References

  1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2018;144(8):1941–53. Available from: http://dx.doi.org/10.1002/ijc.31937
  2. Wahidin M, Noviani R, Hermawan S, Andriani V, Ardian A, Djarir H. Population-Based Cancer Registration in Indonesia. Asian Pacific J Cancer Prev. 2012;13(4):1709–10. Available from: http://dx.doi.org/10.7314/apjcp.2012.13.4.1709
  3. Rhodes A, Yip C. Comparison of breast cancer in Indonesia and Malaysia–A clinico-pathological study between Dharmais cancer centre Jakarta and University Malaya Medical Centre, Kuala Lumpur. Asian Pacific J Cancer Prev. 2011;12:2943–6.
  4. Fleming FJ, Kavanagh D, Crotty TB, Quinn CM, McDermott EW, O’Higgins N, et al. Factors affecting metastases to non-sentinel lymph nodes in breast cancer. J Clin Pathol. 2004;57(1):73–6. Available from: https://pubmed.ncbi.nlm.nih.gov/14693840
  5. Bundred N, Dixon JM, Thomas J. Management of Regional Nodes in Breast Cancer. BMJ. 2013;347(dec19 2):bmj.f3291-bmj.f3291. Available from: http://dx.doi.org/10.1136/bmj.f3290
  6. Lorusso G, Rüegg C. New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol. 2012;22(3):226–33. Available from: http://dx.doi.org/10.1016/j.semcancer.2012.03.007
  7. Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35(5):561–4. Available from: http://dx.doi.org/10.1200/jco.2016.71.0947
  8. Yu K-D, Li J-J, Di G-H, Wu J, Shen Z-Z, Shao Z-M. A straightforward but not piecewise relationship between age and lymph node status in Chinese breast cancer patients. PLoS One. 2010;5(6):e11035–e11035. Available from: https://pubmed.ncbi.nlm.nih.gov/20543953
  9. Ashturkar A V, Pathak GS, Deshmukh SD, Pandave HT. Factors predicting the axillary lymph node metastasis in breast cancer: is axillary node clearance indicated in every breast cancer patient?: factors predicting the axillary lymphnode metastases in breast cancer. Indian J Surg. 2011/05/24. 2011;73(5):331–5. Available from: https://pubmed.ncbi.nlm.nih.gov/23024536
  10. He Z-Y, Wu S-G, Yang Q, Sun J-Y, Li F-Y, Lin Q, et al. Breast Cancer Subtype is Associated With Axillary Lymph Node Metastasis: A Retrospective Cohort Study. Medicine (Baltimore). 2015;94(48):e2213–e2213. Available from: https://pubmed.ncbi.nlm.nih.gov/26632910
  11. Liu N, Yang Z, Liu X, Niu Y. Lymph node status in different molecular subtype of breast cancer: triple negative tumours are more likely lymph node negative. Oncotarget. 2017;8(33):55534–43. Available from: https://pubmed.ncbi.nlm.nih.gov/28903439
  12. Li F, Wu S, Zhou J, Sun J, Lin Q, Lin H, et al. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study. PLoS One. 2014;9(2):e87264–e87264. Available from: https://pubmed.ncbi.nlm.nih.gov/24498305
  13. Boneberg E-M, Legler DF, Hoefer MM, Ohlschlegel C, Steininger H, Füzesi L, et al. Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer. Br J Cancer. 2009;101(4):605–14. Available from: https://pubmed.ncbi.nlm.nih.gov/19672262
  14. Kresno S. Angiogenesis dalam ilmu dasar onkologi. 3rd ed. Jakarta: FKUI; 2012.
  15. Ucuzian AA, Gassman AA, East AT, Greisler HP. Molecular mediators of angiogenesis. J Burn Care Res. 2010;31(1):158–75. Available from: https://pubmed.ncbi.nlm.nih.gov/20061852
  16. Akl MR, Nagpal P, Ayoub NM, Tai B, Prabhu SA, Capac CM, et al. Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget. 2016;7(28):44735–62. Available from: https://pubmed.ncbi.nlm.nih.gov/27007053
  17. Faridi A, Rudlowski C, Biesterfeld S, Schuh S, Rath W, Schröder W. Long-term Follow-up and Prognostic Significance of Angiogenic Basic Fibroblast Growth Factor (bFGF) Expression in Patients with Breast Cancer. Pathol - Res Pract. 2002;198(1):1–5. Available from: http://dx.doi.org/10.1078/0344-0338-00176
  18. Yang X. The Role of VEGF family in angiogenesis, tumor growth and metastasis. Inst för mikrobiologi, tumör-och cellbiologi/Dept of Microbiology, Tumor and …; 2014.
  19. Polat A, Hazar B, Çolak T, Akça T, Karabacak T. Expression of basic fibroblastic growth factor (bFGF) in invasive ductal carcinoma of breast and its relation to angiogenesis and other prognostic parameters. neoplasia. 2005;2(5):7–11.
  20. Liu M, Xing L-Q. Basic fibroblast growth factor as a potential biomarker for diagnosing malignant tumor metastasis in women. Oncol Lett. 2017/06/07. 2017;14(2):1561–7. Available from: https://pubmed.ncbi.nlm.nih.gov/28789380
  21. Yi W, Tang Z, Yang Z, Yu M, Li Y, Chen G. Study on the difference in expression of VEGF and bFGF and their receptors in young and postmenopausal women with breast cancer. Chinese J Clin Oncol. 2004;1(5):354–8. Available from: http://dx.doi.org/10.1007/bf02739676
  22. Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med. 2014;11(2):101.
  23. Sauer G, Schneiderhan-Marra N, Kazmaier C, Hutzel K, Koretz K, Muche R, et al. Prediction of Nodal Involvement in Breast Cancer Based on Multiparametric Protein Analyses from Preoperative Core Needle Biopsies of the Primary Lesion. Clin Cancer Res. 2008;14(11):3345–53. Available from: http://dx.doi.org/10.1158/1078-0432.ccr-07-4802
  24. Wang S, Ding Z. Fibroblast growth factor receptors in breast cancer. Tumor Biol. 2017;39(5):101042831769837. Available from: http://dx.doi.org/10.1177/1010428317698370
  25. Sharpe R, Pearson A, Herrera-Abreu MT, Johnson D, Mackay A, Welti JC, et al. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res. 2011/06/28. 2011;17(16):5275–86. Available from: https://pubmed.ncbi.nlm.nih.gov/21712446

How to Cite

Kartini, D., Panigoro, S. S., Alam, I. A., Dien, A. W., Soemarko, D. S. ., Hellyanti, T., Wardhana, J. D., & Marcevianto, K. V. (2023). Fibroblast growth factor 2 expression on lymph node metastasis in early-stage breast cancer. Bali Medical Journal, 12(1), 621–625. https://doi.org/10.15562/bmj.v12i1.3889
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
4

Total
0

Share

Search Panel

Diani Kartini
Google Scholar
Pubmed
BMJ Journal

Sonar Soni Panigoro
Google Scholar
Pubmed
BMJ Journal

Islam Akbar Alam
Google Scholar
Pubmed
BMJ Journal

Alban Willian Dien
Google Scholar
Pubmed
BMJ Journal

Dewi Sumaryani Soemarko
Google Scholar
Pubmed
BMJ Journal

Tantri Hellyanti
Google Scholar
Pubmed
BMJ Journal

Jessica Dewati Wardhana
Google Scholar
Pubmed
BMJ Journal

Kevin Varian Marcevianto
Google Scholar
Pubmed
BMJ Journal